XERS - Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings is a specialty pharmaceutical company focused on ready-to-use injectable and infusible formulations, with its lead commercial product Gvoke (glucagon injection) for severe hypoglycemia treatment in diabetes patients and Recorlev (levoketoconazole) for endogenous Cushing's syndrome. The company sells primarily to hospitals, specialty pharmacies, and healthcare providers under a prescription pharmaceutical model with payer and formulary-driven reimbursement. Xeris generates sub-$100M in annual revenue, with operations concentrated in the United States and the United Kingdom following its 2021 merger with Strongbridge Biopharma.

Past Year Trends

• Recorlev (levoketoconazole) net product revenues grew approximately 49% year-over-year in FY2024 to roughly $48.5 million, up from $32.5 million in FY2023, making it the primary revenue growth engine as prescribers adopted it as a steroidogenesis inhibitor for endogenous Cushing's syndrome. (Bullish)
• Total Xeris Biopharma net revenues rose approximately 25% in FY2024 to roughly $74 million from $59.5 million in FY2023, though the company remained operating cash flow negative as commercial infrastructure costs for Recorlev weighed on profitability. (Neutral)
• Gvoke (glucagon injection) net product revenues remained essentially flat to slightly declining in FY2024 as Eli Lilly's nasal glucagon Baqsimi continued to erode market share in the U.S. severe hypoglycemia rescue market, limiting Gvoke's growth contribution. (Bearish)

Next Year Trends

• Recorlev's U.S. commercial trajectory faces a peak penetration ceiling in the Cushing's syndrome market, estimated at approximately 15,000–20,000 treated patients annually, with Recordati's Isturisa (osilodrostat) and Corcept's Korlym (mifepristone) holding entrenched prescriber loyalty that constrains Xeris's remaining addressable share gains. (Bearish)
• Xeris's ability to reach operating cash flow breakeven by end of 2026 depends entirely on sustaining double-digit quarterly Recorlev revenue growth; any deceleration in new patient starts or payer coverage restrictions on levoketoconazole could force a dilutive equity raise given the company's negative free cash flow position. (Bearish)
• A potential European regulatory approval or expanded commercial rollout of Recorlev (levoketoconazole) under Xeris's proprietary formulation platform could open an incremental Cushing's syndrome patient population and reduce the company's near-total dependence on U.S. Recorlev revenues for its growth thesis. (Bullish)

Red Flags

No severe red flags identified as of August 2025.